Human epidermal growth factor receptor-2 and topoisomerase II alpha expressions in rectal cancer

Hepato-Gastroenterology

Volumn 58, Issue 106, 2011, Pages 359-363

  Sheng, Liming ^a   Zhu, Yuan ^a   Deng, Qinghua ^a   Wang, Lei ^a   Jin, Qifeng ^a   Luo, Haojie ^a  

^a ZHEJIANG CANCER HOSPITAL   (China)

Author keywords

c erb B2; Immunohistochemistry; Rectal cancer; Topoisomerase II alpha

Indexed keywords

DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE (ATP HYDROLYSING) ALPHA; EPIDERMAL GROWTH FACTOR RECEPTOR 2; UNCLASSIFIED DRUG;

ADULT; AGE; ARTICLE; CANCER INVASION; CANCER STAGING; FEMALE; GENDER; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; LYMPH VESSEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECTUM CANCER; RETROSPECTIVE STUDY; RISK FACTOR; TUMOR DIFFERENTIATION; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; DNA TOPOISOMERASES, TYPE II; DNA-BINDING PROTEINS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM STAGING; RECEPTOR, ERBB-2; RECTAL NEOPLASMS;

EID: 79958175946     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Jemal A, Siegel R, Ward E, et al: Cancer statistics. CA Cancer J Clin 2008; 58:71-96.
2. Landry CS, Brock G, Scoggins CR, et al: A proposed staging system for rectal carcinoid tumors based on an analysis of 4701 patients. Surgery 2008; 144:460-466.
3. Braendengen M, Tveit KM, Berglund A, et al: Randomized phase III study comparing preoperative radiotherapy with chemoradiotherapy in nonresectable rectal cancer. J Clin Oncol 2008; 26:3687-3694.
4. Midgley R, Kerr D: Colorectal cancer. Lancet 1999; 353:391-399. (Pubitemid 29088178)
5. Roels S, Slagmolen P, Nuyts J, et al: Biological image-guided radiotherapy in rectal cancer: is there a role for FM-ISO or FLT, next to FDG? Acta Oncol 2008; 47:1237-1248.
6. Iles S, Gollins S, Susnerwala S, et al: Irinotecan+5-fluorouracil with concomitant pre-operative radiotherapy in locally advanced non-resectable rectal cancer: a phase I/II study. Br J Cancer 2008; 98:1210-1216. (Pubitemid 351481677)
7. Glynne-Jones R, Dunst J, Sebag-Montefiore D: The integration of oral capecitabine into chemoradiation regimens for locally advanced rectal cancer: how successful have we been? Ann Oncol 2006; 17:361-371.
8. Slamon DJ, Leyland-Jones B, Shak S, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344:783-792. (Pubitemid 32222155)
9. Hanna N, Lilenbaum R, Ansari R, et al: Phase II trial of cetuximab in patients with previously treated non-small-cell lung cancer. J Clin Oncol 2006; 24:5253-5258. (Pubitemid 46631370)
10. Coiffier B, Lepage E, Briere J, et al: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346:235-242. (Pubitemid 34438862)
11. Seidman AD, Berry D, Cirrincione C, et al: Randomized phase III trial of weekly compared with every3-weeks paclitaxel for metastatic breast cancer, with Trastuzumab for all HER-2 overexpressors and random assignment to Trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. J Clin Oncol 2008; 26:1642-1649.
12. Wei Q, Chen L, Sheng L, et al: EGFR, HER2 and HER3 expression in esophageal primary tumors and corresponding metastases. Int J Oncol 2007; 31:493-499.
13. Wei Q, Sheng L, Shui Y, et al: EGFR, HER2, and HER3 expression in laryngeal primary tumors and corresponding metastases. Ann Surg Oncol 2008; 15:1193-1201.
14. Shen L, Shui Y, Wang X, et al: EGFR and HER2 expression in primary cervical cancers and corresponding lymph node metastases: implications for targeted radiotherapy. BMC Cancer 2008; 8:232.
15. Cunningham MP, Essapen S, Thomas H, et al: Coexpression of the IGF-IR, EGFR and HER-2 is common in colorectal cancer patients. Int J Oncol 2006; 28:329-335.
16. Park DI, Kang MS, Oh SJ, et al: HER-2/neu overexpression is an independent prognostic factor in colorectal cancer. Int J Colorectal Dis 2007; 22:491-497. (Pubitemid 46488053)
17. Schuell B, Gruenberger T, Scheithauer W, et al: HER 2/neu protein expression in colorectal cancer. BMC Cancer 2006; 6:123.
18. Pavlakis K, Kountourakis P, Stathopoulos E, et al: Her-2 protein expression, cellular localization, and gene amplification in colorectal carcinoma. Appl Immunohistochem Mol Morphol 2007; 15:441-445. (Pubitemid 350307851)
19. Mano MS, Rosa DD, De Azambuja E, et al: The 17q2-q21 amplicon: Her2 and topoisomerase-II alpha and their importance to the biology of solid tumors. Cancer Treat Rev 2007; 33:64-77. (Pubitemid 46132005)
20. Onda T, Toyoda E, Miyazaki O, et al: NK314, a novel topoisomerase II inhibitor, induces rapid DNA double-strand breaks and exhibits superior antitumor effects against tumors resistant to other topoisomerase II inhibitors. Cancer Lett 2008; 259:99-110. (Pubitemid 350235096)
21. Knoop AS, Knudsen H, Balslev E, et al: Retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group. J Clin Oncol 2005; 23:7483-7490. (Pubitemid 46291811)
22. Coon JS, Marcus E, Gupta-Burt S, et al: Amplification and overexpression of topoisomerase II alpha predict response to anthracycline-based therapy in locally advanced breast cancer. Clin Cancer Res 2002; 8:1061-1067. (Pubitemid 35177356)
23. Larsimont D, Durbecq V, Awada A, et al: HER2 and topoisomerase II alpha: useful clinical markers in breast cancer. Bull Cancer 2008; 95:344-351. (Pubitemid 351528772)
24. Zhao H, Yu H, Liu Y, et al: DNA topoisomerase II-alpha as a proliferation marker in human gliomas: correlation with PCNA expression and patient survival. Clin Neuropathol 2008; 27:83-90. (Pubitemid 351428579)
25. Doussis-Anagnostopoulou IA, Vassilakopoulos TP, Thymara I, et al: Topoisomerase IIalpha expression as an independent prognostic factor in Hodgkin's lymphoma. Clin Cancer Res 2008; 14:1759-1766. (Pubitemid 351469461)
26. Staley BE, Samowitz WS, Bronstein IB, et al: Expression of DNA topoisomerase I and DNA topoisomerase II-alpha in carcinoma of the colon. Mod Pathol 1999; 12:356-361. (Pubitemid 29203324)